# **Special Issue**

# Next-Generation Nanoparticles: Innovations in Biomedical Applications and Theranostics

### Message from the Guest Editor

Nanotechnology is a rapidly expanding field in medical sciences that has various applications in the health sector, particularly for the production of bioactive nanomaterials such as nanoparticles (NPs) and nanoconjugates for controlling several diseases. Green nanotechnology-based NPs and nanoconjugates have attracted huge interest because of their extensive biomedical applications. There are numerous types of nanoparticles, such as silver NPs, gold NPs, zinc oxide NPs, titanium dioxide NPs, cobalt NPs, copper (II) NPs, iron NPs, lithium NPs, and magnesium NPs, etc. The core features of these NPs are their small size with large surface area, modification capability, polarity, and property diversity. The application of these bioactive nanoparticles in the biomedical field offers many revolutionary solutions in the development of multifunctionalized drugs and products to control various diseases.

#### **Guest Editor**

Dr. Md Amdadul Huq

Department of Life Sciences, College of BioNano Technology, Gachon University, Seongnam 13120, Gyeongg⊠do, Republic of Korea

#### Deadline for manuscript submissions

31 March 2026



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/235447

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





## **About the Journal**

#### Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).